Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae to Present at the UBS Global Healthcare Conference

Invitae to Present at the UBS Global Healthcare Conference

May 15, 2019

Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at 10:30 a.m. Eastern / 7:30 a.m. Pacific in New York City.

A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available ...

Read more


Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year

Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year

May 07, 2019

On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019
Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), the leader in advanced medical genetics, today announced financial and operating results for the first quarter ended March 31, 2019.

“We’ve seen another first quarter of foundational growth ...

Read more


New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients

New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer Patients

May 03, 2019

Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present a study of more than 6,500 patients with uterine cancer showing that genetic testing provided more than 80 percent of patients with information that made them eligible for precision medicine therapies. The study also highlighted the importance of multigene panel testing versus traditional ...

Read more


Invitae to announce first quarter 2019 financial results on May 7, 2019

Invitae to announce first quarter 2019 financial results on May 7, 2019

April 23, 2019

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is ...

Read more


Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients

Research Underscores Need for Updated Guidelines to Include Multigene Testing for Cancer Patients

April 02, 2019

Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present data from more than 113,000 patients that support updating genetic testing guidelines to include clear recommendations for multigene panel testing in patients with cancer. According to the study, patients with ovarian, breast, pancreatic, prostate and colorectal cancer with potentially actionable germline variants are being missed each year when clinicians adhere to guidelines ...

Read more


Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference

Invitae to Present at the Oppenheimer 29th Annual Healthcare Conference

March 14, 2019

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 1:35 p.m. Eastern / 10:35 a.m. Pacific in New York City.

A live webcast of the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly ...

Read more


Invitae Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

Invitae Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

March 06, 2019

Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters’ option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.00 per share, in connection with Invitae’s recently announced underwritten public offering of 9,000,000 shares of its common stock. As a result of the underwriters’ option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other ...

Read more


Invitae Announces Pricing of Public Offering of Common Stock

Invitae Announces Pricing of Public Offering of Common Stock

March 05, 2019

Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $171.0 million. The offering is expected to close on or about March 8, 2019 ...

Read more


Invitae Announces Proposed Public Offering of Common Stock

Invitae Announces Proposed Public Offering of Common Stock

March 04, 2019

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The ...

Read more


Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures

February 26, 2019

Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure

As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Invitae Corporation (NYSE: NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (NASDAQ: XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis ...

Read more